FEATURED:

Bipartisan leaders of House panel press drug companies on opioid crisis

Bipartisan leaders of House panel press drug companies on opioid crisis
© Getty

Bipartisan leaders of the House Energy and Commerce Committee are pressing three drug companies for answers about their role in the opioid crisis.

The panel’s leaders sent letters to three companies that make opioids, Insys Therapeutics, Mallinckrodt Pharmaceuticals and Purdue Pharma, requesting a briefing with the committee and answers to questions about how the companies marketed opioids and whether they looked the other way when they saw evidence of abuse of their products.

Purdue Pharma, the maker of OxyContin, has long been under scrutiny for misleadingly marketing its product as nonaddictive. The company pleaded guilty in 2007 to misrepresenting the drug’s addictive qualities.

ADVERTISEMENT

The committee’s letter to Purdue questions whether the company actually changed its marketing behavior after 2007.

The letter also points to evidence in media reports that the company knew the drug was being abused earlier than 2000, when officials have said they learned about the problem.

“If Purdue personnel were in fact aware of reports of OxyContin being abused prior to 2000, then that may call into question testimony company executives provided to Congress, including before this Committee,” the lawmakers write.

Earlier this year, Purdue said it would stop marketing opioids to doctors and laid off its sales force.

The letter was signed by the panel’s Chairman, Greg WaldenGregory (Greg) Paul WaldenVulnerable Republicans throw ‘Hail Mary’ on pre-existing conditions GOP senator wants Apple, Amazon to give briefing on reported Super Micro hack Overnight Health Care: Bill banning 'gag clauses' on drugs heads to Trump's desk | Romney opposes Utah Medicaid expansion | GOP candidate under fire over ad on pre-existing conditions MORE (R-Ore.), as well as ranking member Frank Pallone Jr.Frank Joseph PalloneDems eye ambitious agenda if House flips Hillicon Valley: Facebook rift over exec's support for Kavanaugh | Dem worried about Russian trolls jumping into Kavanaugh debate | China pushes back on Pence House Democrat questions big tech on possible foreign influence in Kavanaugh debate MORE (D-N.J.) and Reps. Gregg HarperGregory (Gregg) Livingston HarperGOP lawmakers urge improvements to cyber vulnerabilities resource Bipartisan leaders of House panel press drug companies on opioid crisis Republican chairman wants FTC to review mergers of drug price negotiators MORE (R-Miss.), Diana DeGetteDiana Louise DeGetteLive coverage: Social media execs face grilling on Capitol Hill Women poised to take charge in Dem majority Bipartisan leaders of House panel press drug companies on opioid crisis MORE (D-Colo.), Morgan GriffithHoward (Morgan) Morgan GriffithVirginia reps urge Trump to declare federal emergency ahead of Hurricane Florence Conservatives blame McCarthy for Twitter getting before favorable committee Bipartisan leaders of House panel press drug companies on opioid crisis MORE (R-Va.) and Kathy CastorKatherine (Kathy) Anne CastorBipartisan leaders of House panel press drug companies on opioid crisis Overnight Health Care: Trump officials explore importing prescription drugs | Key ObamaCare, drug pricing regs under review | GOP looks to blunt attacks on rising premiums | Merck to lower some drug prices House Dems want answers on cuts to ObamaCare outreach groups MORE (D-Fla.).

The committee has been investigating the opioid crisis for months, including looking into “pill dumping,” where drug distributors flooded small towns, particularly in West Virginia, with millions of opioid pills.